Chordate Medical

Chordate Medical is a medtech company that has developed, patented and CE-marked a drug-free treatment technology for chronic migraine and chronic rhinitis.

[Chordate Medical @ChordateMedical]

During @ihs_official's International Headache Congress in Seoul on September 14-17, Chordate Medical is introducing the new brand Ozilia™ Migraine for the company’s migraine treatment. https://t.co/IN44OcMUcd

[Chordate Medical @ChordateMedical]

Notice of Extraordinary General Meeting of Chordate Medical Holding AB (publ): https://t.co/3UJXDU5wHy

[Chordate Medical @ChordateMedical]

Chordate decides on a conditional directed new issue of Preference Shares of approximately SEK 2.55 million: https://t.co/eDlD7YQdph

[Chordate Medical @ChordateMedical]

Chordate presents conclusions from second data monitoring of ongoing open-label long-term chronic migraine study, PM010:

“It is very gratifying that PM010 now with statistical significance further confirms the results from the PM007 study."

Read more: https://t.co/GU2wSDKybp

[Chordate Medical @ChordateMedical]

Chordate Medical Holding AB (publ) Interim Report January-March 2025: https://t.co/7mwuSYdNb4

[Chordate Medical @ChordateMedical]

Communiqué from the Annual General Meeting of Chordate Medical Holding AB (publ): https://t.co/Iq9ODe5KG1

[Chordate Medical @ChordateMedical]

.@BioStock_SWE interview with Chordate CEO Anders Weilandt: "New distributor strengthens Chordate Medical’s investment in Saudi Arabia".
https://t.co/eMKoBqfMXc

[Chordate Medical @ChordateMedical]

Chordate Medical has appointed Narro Trading Est. (Narro Medical) as a non-exclusive distributor in Saudi Arabia. Narro Medical will initially focus on the migraine segment. https://t.co/1l7f1U2Mhe

[Chordate Medical @ChordateMedical]

Chordate Medical hereby announces that the company has terminated the agreement with Lago Kapital regarding the assignment as liquidity provider for the preference share CMH Pref: https://t.co/GmR6IXgyH7

[Chordate Medical @ChordateMedical]

Notice to the Annual General Meeting in Chordate Medical Holding AB (publ): https://t.co/RVqS5FkIGb

[Chordate Medical @ChordateMedical]

Chordate Medical Holding AB publishes annual report for 2024: https://t.co/mmxZ1dPrQZ

[Chordate Medical @ChordateMedical]

Chordate Medical Receives Trademark Registration for Ozilia® in the United States: https://t.co/Qe36KO1N2t

[Chordate Medical @ChordateMedical]

.@SvD highlights Chordate Medical’s migraine treatment Ozilia in a new feature – and meets one of the first Swedes to try the method. Read more: https://t.co/Iwwwib9qW9

[Chordate Medical @ChordateMedical]

Chordate Medical CEO Anders Weilandt presents the year end report at @FinwireMedia: https://t.co/yuan02Qp6C

[Chordate Medical @ChordateMedical]

Year-End Report Chordate Medical Holding AB January – December 2024: "Market breakthrough and last step toward exit". https://t.co/zaY7Qw24EU

[Chordate Medical @ChordateMedical]

Chordate Medical Holding’s Preference Share Admitted to Trading on Nasdaq First North Growth Market with First Trading Day on March 17th, 2025: https://t.co/mzkHgCYjlp

[Chordate Medical @ChordateMedical]

Chordate Medical Holding AB carries out a directed set-off issue to underwriters in the completed rights issue: https://t.co/2nCgMgfxoI

[Chordate Medical @ChordateMedical]

Chordate Medical announces the outcome of the rights issue: https://t.co/wDuS9i4qdV

[Chordate Medical @ChordateMedical]

The subscription period for Chordate Medical’s ongoing rights issue runs until Monday, February 17. Read more: https://t.co/0L08mCQwZr

[Chordate Medical @ChordateMedical]

Correction: Additional Major Shareholders Announce Full Subscription in Chordate Medical’s Ongoing Rights Issue: https://t.co/wxArP0HhIe

[Chordate Medical @ChordateMedical]

Additional Major Shareholders Announce Full Subscription in Chordate Medical’s Ongoing Rights Issue. https://t.co/Ixn8ehQVMq